Thus, while knockdown of ChREBP reduces Dex-induced glycolysis, it does not attenuate chronic Dex-induced hypertriglyceridemia and hepatic steatosis despite the decreased expression of certain lipogenic genes. The gene discussed is MLXIPL; the disease is hypertriglyceridemia.